Regeneron Pharmaceuticals has grown revenue 7.0% a year over three years and 4.6% a year over five, with earnings per share compounding at 2.3%. Revenue growth, 3-year annual rate: +7.0% (Biotechnology median +17%). Revenue growth, 5-year rate: +4.6%, growth has picked up over the last three years. Earnings per share, 3-year rate: +2.3%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 18, FY2008 to FY2025, as filed.

REGNRegeneron Pharmaceuticals

Healthcare

$746.46+25% 1Y

$746.46

$553.3252 weeks$852.16

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−2.2 points).

1 to watch, 2 neutral

Revenue trend+9% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +5% a year.

Earnings trend+2% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−2.2 points operating

Trailing-twelve-month operating margin, 24.5% now against 26.7% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsmiddle of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is REGN growing?

Regeneron Pharmaceuticals has grown revenue 7.0% a year over three years and 4.6% a year over five, with earnings per share compounding at 2.3%.

+7.0%

Revenue growth, 3-year annual rate · Biotechnology median +17% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +4.6%
Revenue growth, 5-year rate · +7.0% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +2.3%
Earnings per share, 3-year rate · revenue +7.0% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 18
Years of annual history on file · FY2008 to FY2025, as filed